Friday, December 29, 2017

ChineseInvestors.com, Inc. (CIIX) CEO Remains Bullish on Bitcoin and Other Cryptocurrencies

  • Warren Wang, CEO of CIIX, said in a podcast interview that investors in China and the Chinese-speaking community in the U.S. and Canada want to learn more about bitcoin, cryptocurrencies
  • CIIX doubles down on commitment to its bitcoin division, adding a bitcoin ATM in its California headquarters and broadcasting a daily video from the NYSE called ‘Bitcoin Multimillionaire’
  • Company’s goal in FY2018 is profit, lower costs and a greater than 100 percent YOY sales increase
ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang remains bullish on the future of bitcoin and other cryptocurrencies, and he recently said in a podcast interview that the Chinese-speaking community worldwide is eager to learn more about buying and managing digital currencies. Despite China’s ban on trading cryptocurrencies on a regulated exchange, he noted, many Chinese investors are buying and selling them on unregulated offline platforms.
In an interview with the Bad Crypto Podcast (http://nnw.fm/oO7WI), Wang explained that the Chinese investor is an important target for cryptocurrency entrepreneurs. “The Chinese investor is an advocate of gambling,” he explained. “Most today trade bitcoin and other cryptocurrencies on the offline market. The Chinese-speaking people within China and also in North America — the U.S. and Canada — are excited about bitcoin.”
CIIX recently hosted and installed a Bitcoin ATM in the lobby of its San Gabriel, California, headquarters (http://nnw.fm/VIa3n). Wang called it the first ever by a Chinese company in the U.S. The company also recently attended a Toronto cryptocurrency roadshow and educational seminar on how to buy, sell and manage these coins, he noted in the interview. CIIX has doubled down on its commitment to bitcoin. It produces a daily video from the NYSE called ‘Bitcoin Multimillionaire’ focused on news of the currency (http://nnw.fm/Lfrx8).
The company addresses Chinese-speaking audiences worldwide on the subject of investing in bitcoin and other cryptocurrencies, and now, with the ATM, it is actively involved in their trade. Wang has set the goals for CIIX in FY2018 as profitability, lower costs and greater than 100 percent year-over-year revenue growth (http://nnw.fm/Q9zhQ).
Wang said that despite the lack of a regulated Chinese exchange to trade cryptocurrencies and the Chinese government’s ”badmouthing” of bitcoin though its official TV media outlet, there is a great desire by the Chinese-speaking people within China and North America to buy, sell and trade bitcoin.
“Real estate is very expensive and so are labor and rents in China,” he said. “Investors have a high savings rate. They now would like to make bitcoin and other cryptocurrencies part of their assets. They are trading offline on platforms of decentralized exchanges to do so.”
He advised entrepreneurs within the industry to be patient while the Chinese investment community learns about issues like the digital wallets used for buying, selling and managing bitcoin. “The average Chinese investor may have up to $5,000 to invest in these currencies,” he said. “But be patient.”
Wang said that, in the future, China may organize a regulated market for the trading of cryptocurrencies in order to keep monies involved in that trading within China. “But, until now, this has not happened,” he concluded.
For more information, visit the company’s website at www.ChineseInvestors.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Posted by at No comments:

Skinvisible, Inc. (SKVI) and Quoin Poised to Tackle Opioid Crisis with Alternative Pain Therapies

  • A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies
  • The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management
  • Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start
A recent article by the Washington Post (http://nnw.fm/ikb1U) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than originally thought. The story alludes to the possibility that “drug manufacturers and distributors turned a willfully blind eye toward illegal drug trafficking.” In the midst of this, there is an opioid epidemic that has been deemed a national health emergency that results in 90 deaths per day (http://nnw.fm/V60zK) and is growing exponentially, according to the Centers for Disease Control and Prevention.
There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed merger, with expected completion in early 2018, that will result in a new entity, Quoin Pharmaceuticals Inc. Upon completion of this merger, the new company (combining Quoin’s strengths of pharmaceutical development and Skinvisible’s innovative technologies that enhance delivery and product performance) has tremendous potential to address the significant needs of the pain management market.
One of the main areas of Quoin’s focus is to disrupt the opioid market (currently estimated at $6 billion annually in the U.S. alone) and produce and deliver to market non-opioid products that serve as effective and viable alternatives for the immense pain management market. This focus will include all areas of pain management, including critical needs in the post-surgical setting. At least 50 million U.S. surgeries require the use of post-operative pain management pharmaceuticals annually, and it is in the post-surgical setting that about 50 percent of opioid addictions begin.
To address the critical demands for effective alternatives to opioids, Quoin will launch one of its first lead products, QRX001, for effective treatment of post-surgical pain. The product, a transdermal NMDA receptor antagonist, delivers up to 72 hours of effective post-surgical pain relief. With the aim of providing alternatives to opioids as well as opiates, numerous clinical studies on QRX001 have shown that sub-anesthetic doses have resulted in a marked 24-hour reduction in PCA morphine consumption. In addition, clinical tests of the NMDA receptor antagonist generated superior results to any single existing product or combination and resulted in mild or absent adverse events, reduced post-surgical nausea and vomiting and reduced pain intensity.
With completion of the merger of Skinvisible and Quoin expected in early 2018, the synergies of the merged technologies, expertise and proven track records poise the new Quoin Pharmaceuticals with tremendous potential to address the needs of the immense pain market and tackle the opioid epidemic head-on.
For more information, visit the company’s website at www.Skinvisible.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Posted by at No comments:

Wednesday, December 27, 2017

World Health Organization Officially Rules CBD Should Not be a Scheduled Drug

  • The World Health Organization (WHO) announced that “the cannabis compound CBD (Cannabidiol) should not be internationally scheduled as a controlled substance” (www.WHO.int)
  • WHO has issued preliminary findings indicating that cannabidiol (CBD) shows “no indications of abuse or dependence potential” and “a good safety profile”
  • MCOA is committed to the development of high quality CBD-based products
The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. The CBD pre-review report (http://nnw.fm/aYG6D), as issued by the agency, states, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential.” The report further indicates that, “CBD is generally well tolerated and with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.”
The wholly-owned subsidiary of Marijuana Company of America Inc. (OTC: MCOA), hempSMART™, Inc. is an affiliate marketing company that develops and brings to market hemp-derived cannabinoid-based formulations that are combined with other natural botanicals to create high quality wellness products. HempSMART’s products are now available on the company’s website, www.hempSMART.com. They include hempSMART™ Brain (http://nnw.fm/y5WGz), created as a nootropic product; hempSMART™ Full Spectrum Drops (http://nnw.fm/h5KqL), with more bioavailability; and the newly-released hempSMART™ Pain Capsules (http://nnw.fm/h5KqL).
In a news release, Paula Vetter, a member of hempSMART’s product development team, stated, “HempSMART demonstrated its commitment to formulating a safe and synergistic natural personal care product. The hempSMART Pain formula harnesses the natural power of premium CBD, CBG and active terpenes derived from industrial hemp, combined with complimentary botanicals. Our team is focused on the development of premium personal care products for our customers.”
About hempSMART™ Pain
hempSMART™ Pain Capsules are formulated with 10mg of full dpectrum, non-psychoactive cannabidiol (CBD) per serving, derived from industrial hemp as the core ingredient, which, along with a proprietary blend of other natural ingredients, delivers an all-natural formulation for the temporary relief of minor pain associated with physical activity.
Disclaimer:
  • These statements have not been evaluated by the Food and Drug Administration
  • This product is not intended to treat, cure, or prevent any disease
For more information, visit the company’s websites at www.MarijuanaCompanyofAmerica.com and
www.hempSMART.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Posted by at No comments:
Subscribe to: Posts (Atom)